Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symlin Dose Escalation in Type 2 Diabetes
NCT01137695Phase 3Unknown
- Start
- May 2010
- Primary completion
- Jan 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of pramlintide in type 2 diabetes mellitus (T2DM). Status: unknown.
02
Drugs
pramlintide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01137695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01137695.